跳到主要內容

臺灣博碩士論文加值系統

(98.84.25.165) 您好!臺灣時間:2024/11/11 16:08
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:張勝皇
研究生(外文):Sheng-Huang Chang
論文名稱:大蒜精油對糖尿病大鼠心臟病變的影響評估與精神分裂症病人單核球輔助型T細胞激素及TLR訊息RNA表現之分析
論文名稱(外文):The Assessment of Impact about Garlic Oil on Cardiomyopathy in Diabetic Rats and Analysis of T cell Cytokines and TLR mRNA Expression in Patients with Schizophrenia
指導教授:曾博修曾博修引用關係
學位類別:博士
校院名稱:中山醫學大學
系所名稱:生化暨生物科技研究所
學門:生命科學學門
學類:生物科技學類
論文種類:學術論文
論文出版年:2014
畢業學年度:102
語文別:中文
論文頁數:34
相關次數:
  • 被引用被引用:0
  • 點閱點閱:263
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
PART Ⅰ
糖尿病(Diabetes Mellitus, DM)是一種慢性的代謝異常疾病,導因於患者無法有效利用血糖,使體內血糖過高,長期誘發相關併發症,影響病人存活。目前已有相當多文獻指出大蒜精油可以有效控制血糖、促進血液纖維蛋白分解、降血脂、降血膽固醇濃度、抗氧化等進而保護心血管系統,然而保護機制尚未明朗,本研究於是以罹患糖尿病大白鼠動物實驗模式來探討大蒜精油是否可以改善心臟細胞肥大和心肌纖維化的發生。
我們採用由STZ誘導糖尿病的大白鼠,經過確認尿糖及血糖的濃度,觀察誘發糖尿病成功的大白鼠,每2天餵食大蒜精油一次,共餵食16天(Control、0mg/kgBw、10mg/kgBw、500mg/kgBw、100mg/kgBw)後,心臟之胚胎基因(ANP、BNP)和心臟肥大訊息路徑(ERK、JNK、P38、IL-6)以及心肌纖維化訊息路徑(uPA、PAI-1)相關的蛋白表現。
結果得知,心臟肥大及心肌纖維化相關蛋白的表現,因處理大蒜精油而下降,改善糖尿病引起的心臟肥大和心肌纖維化,且呈現dose-dependent的情形。心臟超音波的檢查結果,也顯示大蒜精油也具有改善心臟收縮之功能。由此可知,大蒜精油透過抑制MAPKs (ERK、JNK、P38)、IL-6與uPA、PAI-1之表現,改善糖尿病引起的心臟肥大和心肌纖維化現象。
PART Ⅱ
目前對於細胞激素在於精神分裂症的免疫調節機制及致病機轉之關聯瞭解仍然有限。因此本計畫目的是為瞭解調控體內免疫環境之輔助型T細胞激素(T helper cell cytokine)與Toll-like receptors(TLRs)表現狀況及關聯性,在精神分裂症病人與正常人之差異,從中找出可以作為診斷及判別指標之參考。進而應用到其他疾病的治療或預防。
收集經診斷罹患精神分裂症且常規服用抗經神病藥物的男性病人(n=46;平均年齡40±10.8)與沒有服用藥物的正常男性(n=22;平均年齡33±5.9)之周邊血液與血球進行TLRs與細胞激素基因表現的變化。
本研究發現精神分裂症病人單核球中,其IL-4及IL-10的mRNA表現比率,較正常人單核球的表現比率高,而TLR-3及TLR-5的表現比率,較正常人單核球的表現比率低。顯然精神分裂症病人,其免疫調節基因轉錄層次確與正常人不同。
精神分裂症病人單核球之IL-4與IL-10之mRNA比起正常人有較高之表現率,加上較低的TLR-3及TLR-5之mRNA的表現率。這是首次有這樣的發現,或許可作為精神分裂症病人遺傳的線索。相信對於精神分裂症之診斷及癒後之追蹤,可以提供有效之輔助生物標記。另外,精神分裂症是一種慢性疾病,致病的成因雖不清楚,目前仍無法根治,但是由IL-4、IL-10蛋白表現與正常人相仿的實驗結果,我們認為與精神分裂症住院病人接受持續之醫療照護,固定接受抗精神病藥物之治療有關。

PART Ⅰ
Diabetes is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The diabetic patient can not use glucose effectively with hyperglycemia which will induce related comorbidity that will effect the patient’s survival.
Garlic oil has been reported to promote fibrinogenolysis, reduce cholesterol, inhibits the oxidation and protect the cardiovascular system; however, the effects and mechanisms behind the cardioprotection of garlic oil on diabetes-induced cardiomyopathy (e.g., cardiac hypertrophy and fibrosis ) are unclear. We used streptozotocin (STZ)-induced diabetic rats to investigate whether garlic oil could protect the heart from diabetes-induced cardiomyopathy. Wistar STZ-induced diabetic rats received garlic oil (0, 10, 50 or 100 mg kg−1 body weight) by gastric gavage every 2 days for 16 days. Normal rats without diabetes were used as control.
Then cardiac embryo proteins(atrial natriuretic peptide (ANP) and B-type natriuretic peptide (BNP)), cardiac fibrosis by uPA and PAI-1, signaling pathway for cardiac hypertrophy-related mitogen-activated protein kinases (MAPK) pathways (e.g., p38, c-Jun N-terminal kinases (JNK) and extracellular responsive kinase (ERK1/2)) , the IL-6/MEK5/ERK5 signaling pathway related protein were observed.
The results revealed that cardiac hypertrophy and fibrosis related proteins were reduced after garlic oil treatment, and were improve in dose-dependent variable. The echocardiography showed garlic oil could better the contraction cardiac contractile function. The garlic oil could suppress MAPKs(ERK1/2, p38, JNK), IL-6 and uPA, PAI-1 representation to alleviate cardiac hypertrophy and fibrosis caused by diabetes mellitus of rats.
PART Ⅱ
There is limited understanding about immune regulation mechanism and etiology of schizophrenic patients. In the study, we tried to understand the presentation and relationship between immune regulatory T helper cell cytokines and Toll-like receptors(TLRs)in schizophrenic patients and normal controls. We hope we can find some indicators to aid on diagnosis, treatment and prevention of schizophrenia and other diseases.
46 schizophrenic male patients(average age 40±10.8)who were using antipsychotic medication regularly and 22 drug-naïve normal males(average age 33±5.9)were enrolled in this study . we collected their peripheral blood samples and blood cells for cytokine and TLRs presentation analysis.
In our study, we found the mRNA presentation rate in IL-4 and IL-10 in monocytes are higher, but TLR-3 and TLR-5 are lower in schizophrenic patients than in normal control. Obviously the immune regulation gene transcriptions were different between schizophrenic patients and normal controls.
The presentation rate in mRNA of IL-4and IL-10 are higher, but TLR-3 and TLR-5 are lower in monocytes among schizophrenic patients. This finding may be used in genetic counseling for diagnosis of schizophrenic patients as a useful biological maker. In addition, after continuous antipsychotic treatment, the IL-4 and IL-10 protein presentation were similar between schizophrenic patients and normal controls. So it is important to push schizophrenic patients to receive continuous treatments and relapse prevention for the sake of their safty and health.

PART Ⅰ
一、縮 寫 表 2
二:中文摘要 3
三:英文摘要 4
四:緒論 5
五:研究動機 29
六:研究架構 31
七:實驗材料與方法 32
八:結果 38
九:討論 41
十:參考文獻 43
十一:圖表 48
PART Ⅱ
一、縮 寫 表 2
二:中文摘要 3
三:英文摘要 4
四:緒論 5
五:研究動機 10
六:研究架構 11
七:實驗材料與方法 12
八:結果 15
九:討論 19
十:參考文獻 21
十一:圖表 24

PART Ⅰ
1. American Diabetes Association (2013) Diagnosis and classification of diabetes mellitus. Diabetes care 36: S67–74
2. Marian AJ, Roberts R (1995) Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation 92 : 36–1347
3. Marian, A.J., Roberts, R. (1995) Recent advances in the molecular genetics of hypertrophic cardiomyopathy. Circulation, 92 , 36–1347
4. Boheler, K.R., Schwartz, K. (1992) Gene expression in cardiac hypertrophy. Trends Cardiovasc Med., 5 ,176–182
5. Boheler KR, Schwartz K (1992) Gene expression in cardiac hypertrophy. Trends Cardiovasc Med 5 : 176–182
6. Sugden, P.H., and Clerk, A. (1998) Cellular mechanisms of cardiac hypertrophy. J. Mol. Med., 76, 725–746
7. Colucci WS, and Braunwald E (1997) in Heart Disease (Braunwald, E., ed), 5th Ed., pp. 399-401 W. B. Saunders Co., Philadelphia, PA
8. Nag AC, Cheng M (1986) Biochemical evidence for cellular dedifferentiation in adult rat cardiac muscle cells in culture: expression of myosin isozymes. Biochem Biophys Res Commun 137 : 855–862
9. Eppenberger-Eberhardt M, Flamme I, Kurer V, Eppenberger HM (1990) Reexpression of alpha-smooth muscle actin isoform in cultured adult rat cardiomyocytes. Dev Biol 139 : 269–278
10. Eppenberger-Eberhardt M, Messerli M, Eppenberger HM, Reinecke M (1993) New occurrence of atrial natriuretic factor and storage in secretorially active granules in adult rat ventricular cardiomyocytes in long-term culture. J Mol Cell Cardiol 25 : 753–757
11.Seger R, Krebs EG (1995) The MAPK signaling cascade. Faseb J 9 : 726–735
12.Treisman R (1996) Regulation of transcription by map kinase cascades. Curr Opin Cell Biol 8 : 205–215
13.Cook JL, Bhandaru S, Giardian JF, Calycomb WC, Re RN (1995) Identification and antisense inhibition of a renin–angiotensin system in transgenic cardiomyocytes. Am J Physiol 268 : H1471–H1482
14.Sadoshima J, Xu Y, Slayter HS, Izumo S (1993) Autocrine release of angiotensin II mediates stretch-induced hypertrophy of cardiac myocytes in vitro. Cell 75 : 977–984.
15.Shubeita HE, McDonough PM, Harris AN et al (1990) Endothelin induction of inositol phospholipid hydrolysis, sarcomere assembly, and cardiac gene expression in ventricular myocytes. A paracrine mechanism for myocardial cell hypertrophy. J Biol Chem 265 : 20555–20562
16.Yamazaki T, Komuro I, Kudoh S et al (1996) Endothelin-1 is involved in mechanical stress-induced cardiomyocyte hypertrophy. J Biol Chem 271 : 3221–3228
17.Komuro I, Katoh Y, Kaida T et al (1991) Mechanical loading stimulates cell hypertrophy and specific gene expression in cultured rat cardiac myocytes. J Biol Chem 266 : 1265–1268
18.Kariya K, Karns LR, Simpson PC (1991) Expression of a constitutively activated mutant of the beta-isozyme of protein kinase C in cardiac myocytes stimulates the promoter of the beta-myosin heavy chain isogene. J Biol Chem 266 : 10023–10026
19.Yazaki Y, Komuro I, Yamazaki T et al (1993) Role of protein kinase system in the signal transduction of stretch-mediated protooncogene expression and hypertrophy of cardiac myocytes. Mol Cell Biochem 119 : 11–16
20.Molkentin JD, Lu J, Antos CL et al (1998) A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 93 : 215–228
21.Sussman MA, Lim HW, Gude N et al (1998) Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 281 : 1690–1693
22.Shimoyama M, Hayashi D, Takimoto E et al. Calcineurin plays a critical role in pressure overload-induced cardiac hypertrophy. Circulation 1999;100:2449–2454
23.Sturgill TW, Wu J (1991) Recent progress in characterization of protein kinase cascades for phosphorylation of ribosomal protein S6 (minireview). Biochim Biophys Acta 1092 : 350–357
24.Zheng C, Guan K (1994) Activation of MEK family kinases requires phosphorylation of two conserved ser / thr residues. EMBO J 13 : 1123–1131
25.Cobb MH, Robbins DJ, Boulton TG (1991) ERKs, extracellular signal-regulated MAP-2 kinases. Curr Opin Cell Biol 3 : 1025–1032
26.Sadoshima J, Qiu Z, Morgan JP, Izumo S (1995) Angiotensin II and other hypertrophic stimuli mediated by G protein-coupled receptors activate tyrosine kinase, mitogen-activated protein kinase, and 90-kD S6 kinase in cardiac myocytes. Circ Res 76 : 1–15
27.Clerk A, Sugden PH (1997) Cell stress-induced phosphorylation of ATF2 and c-jun transcription factors in rat ventricular myocytes. Biochem J 325 : 801–810
28.Wang Y, Huang S, Sah VP et al (1998) Cardiac muscle hypertrophy and apoptosis induced by distinct members of the p38 mitogen-actiwith vated protein kinase family. J Biol Chem 273 : 2161–2168
29.Schindler C, Darnell JEJ (1995) Transcriptional responses to polypeptide ligands: The JAK-STAT pathway (review). Annu Rev Biochem 64 : 621–651
30.Takahashi T, Fukuda K, Pan J et al (1999) Characterization of insulin-like growth factor-1-induced activation of the JAK/STAT pathway in rat cardiomyocytes. Circ Res 85 : 884–891
31.Mascareno E, Dhar M, Siddiqui MAQ (1998) Signal transduction and activator of transcription (STAT) protein-dependent activation of angiotensinogen promoter: a cellular signal for hypertrophy in cardiac muscle. Proc Natl Acad Sci USA 95: 5590–5594
32.Pan J, Fukuda K, Saito M et al (1999) Mechanical stretch activates the JAK/STAT pathway in rat cardiomyocytes. Circ Res 84 : 1127–1136
33.Hirota H,Chen J, Betz UA,Rajewsky K,Gu Y,et al.(1999)Loss of a gp130 cardiac muscle cell survival pathway is a critical event in the onset of heart failure during biomechanical stress. Cell, 97, 189-198
34.Rebekka L, Nicol Norbert, Frey, Gray, Pearson, Melanie, Cobb, James, Richardson, and Eric, N., Olson, (2001) Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy. EMBO J. 20, 2757-2767.
35.Zhou G, Bao ZQ and Dixon JE (1995) Components of a new human protein kinase signal transduction pathway. J. Biol. Chem., 270, 12665–12669.
36.English JM, Vanderbilt CA, Xu S, Marcus S and Cobb MH (1995) Isolation of MEK5 and differential expression of alternatively spliced forms. J. Biol. Chem., 270, 28897–28902.
37.Kato Y, Kravchenko VV, Tapping RI, Han J, Ulevitch RJ and Lee JD (1997) BMK1/ERK5 regulates serum-induced early gene expression through transcription factor MEF2C. EMBO J., 16, 7054–7066.
38.Fukuhara S, Marinissen MJ., Chiariello M and Gutkind JS (2000) Signaling from G protein-coupled receptors to ERK5/Big MAPK 1 involves G q and G 12/13 families of heterotrimeric G proteins. Evidence for the existence of a novel Ras and Rho-independent pathway. J. Biol. Chem., 275, 21730–21736.
39.Takeishi Y, Abe J, Lee JD, Kawakatsu H, Walsh RA and Berk BC(1999) Differential regulation of p90 ribosomal S6 kinase and big mitogen-activated protein kinase 1 by ischemia/reperfusion and oxidative stress in perfused guinea pig hearts. Circ. Res., 85, 1164–1172.
40.Kamakura S, Moriguchi T and Nishida E (1999) Activation of the protein kinase ERK5/BMK1 by receptor tyrosine kinases. Identification and characterization of a signaling pathway to the nucleus. J. Biol. Chem., 274, 26563–26571.

41.Silagy C, and Neil A (1994) Garlic as a lipid lowering agent-a meta-analysis. J R Coll Physicians Lond 28: 39-45
42.Amagase H, and Milner JA (1993) Impact of various sources of garlic and their constituents on 7,12-dimenthylbenz〔a〕anthracene binding to mammary cell DNA. Carcinogenesis 14: 1627-31
43.Jain RC, Vyas CR, Mahatma OP (1973) Hypoglycemic action of onion and garlic. Lancet 29: 1491
44.Manabe I, Shindo T, and Nagai R (2002) Gene expression in fibroblasts and fibrosis:involvement in cardiac hypertrophy. Circ Res 91:1103-1113
45.Schnee J M and Hsueh W A (2000) Angiotensin II, adhesion, and cardiac fibrosis. Cardiovasc Res 46:264-268
46.Krenz M, Robbins J (2004) Impact of beta-myosin heavy chain expression on cardiac function during stress. J Am Coll Cardiol. 44:2390-2397
47.Sambola Liekens E D C, Johan Neyts (2001) Angiogenesis:regulators and clinical application. Biochemical Phamacology 61:253-270
48.Morris C A, Avorn J (2003) Internet marketing of herbal products. JAMA 290:1505-1597
49.Blumenthal M(2003) Herbs continue slide in mainstream market:Sales down 14 percent. Herbal Gram 58,71.
50.Agarwal K (1996) Therapeutic actions of garlic constituents. Medicinal Res Rev 16:111-124.
51.Amagase H, Petesch BL, Matsuura H, Kasuga S, Itakura Y. (2001) Recent advances on the nutritional effects associated with the use of garlic as a supplement: intake of garlic and its bioactive components. J Nutr. 131(3):955S-962S.
52.Sheen LY,Lin SY and Tsai SJ (1992) Odor assessments for volatile compounds of garlic and ginger essential oil by sniffing method of gas chromatography. J Chin Agric Chem Soc. 30:14-24
53.Bordia A, Verma SK, Srivastava KC (1998) Effect of garlic (Allium sativum) on blood lipids, blood sugar, fibrinogen and fibrinolytic activity in patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids. 58:257-63.
54.Banerjee SK, Maulik SK (2002) Effect of garlic on cardiovascular disorders: a review Nutr J. 1:4.
55.Keiss Hans-Peter, Verena M, Dirsch, Thomas H, Thomas H, Laurence T, Jacques A, Rémi K, and Angelika MV (2003) The American Society for Nutritional SciencesGarlic (Allium sativum L.) Modulates Cytokine Expression in Lipopolysaccharide-Activated Human Blood Thereby Inhibiting NF-κB Activity. J. Nutr. 133: 2171-2175
56. Augusti KT, Sheela CG (1996) Antiperoxide effect of S-allyl cysteine sulfoxide, an insulin secretagogue, in diabetic rats. Experientia 52:115-120.
57. Moriwaki H, Stempien-Otero A, Kremen M, Cozen AE, Dichek DA (2004) Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. Circ Res. 95: 637–644.
58. Ghosh AK, Bradham WS, Gleaves LA, De Taeye B, Murphy SB, Covington JW, Vaughan DE (2010) Genetic deficiency of plasminogen activator inhibitor-1 promotes cardiac fibrosis in aged mice: involvement of constitutive transforming growth factor-beta signaling and endothelial-to-mesenchymal transition. Circulation. 122(12):1200-1209.
PART Ⅱ
1. Sullivan PF, Kendler KS, Neale MC (2003) Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 60:1187- 1192
2. Kendler KS, Gallagher TJ, Abelson JM, Kessler RC (1996) Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey Arch Gen Psychiatry 53:1022-1031
3 Gallinat J, Bajbouj M, Sander T, Schlattmann P, Xu K, Ferro EF, Goldman D, Winterer G (2003) Association of the G1947A COMT (Val(108/158)Met) gene polymorphism with prefrontal P300 during information processing. Biol Psychiatry 54:40-48
4 Winterer G, Egan MF, Raedler T, Sanchez C, Jones DW, Coppola R, Weinberger DR (2003) P300 and genetic risk for schizophrenia. Arch Gen Psychiatry 60:1158-1167
5 Glahn DC, Therman S, Manninen M, Huttunen M, Kaprio J, Lonnqvist J, Cannon TD (2003) Spatial working memory as an endophenotype for schizophrenia. Biol Psychiatry 53:624-636
6 Fanous AH, Neale MC, Gardner C O, Webb BT, Straub RE, O’neill FA, Walsh D, Riley BP, Kendler KS (2007) Significant correlation in linkage signals from genome-wide scans of schizophrenia and schizotypy. Mol Psychiatry 12:958-965
7 Bechter K (2004) The mild encephalitis-hypothesis—new findings and studies. Psychiatr Prax 31:S41-43
8 Muller N, Schwarz M (2006) Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res 10:131-148
9 Schwarz MJ, Riedel M, Ackenheil M, Muller N (2000) Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients. Biol Psychiatry 47:29-33
10 Avgustin B, Wraber B, Tavcar R(2005) Increased Th1 and Th2 immune reactivity with relative Th2 dominance in patients with acute exacerbation of schizophrenia. Croat Med J 46:268-274
11 Zhang XY, Zhou DF, Zhang PY, Wu GY, Cao LY, Shen YC (2002) Elevated interleukin-2, interleukin-6 and interleukin-8 serum levels in neuroleptic-free schizophrenia: association with psychopathology. Schizophr Res 57:247-258
12 Rudolf S, Peters M, Rothermundt M, Arolt V, Kirchner H. (2002) The influence of typical and atypical neuroleptic drugs in the production of interleukin-2 and interferon-gamma in vitro. Neuropsychobiology 46:180-185
13 Akhondzadeh S, Tabatabaee M, Amini H, Ahmadi Abhari SA, Abbasi SH, Behnam B (2007) Celecoxib as adjunctive therapy in schizophrenia: a double-blind, randomized and placebo-controlled trial. Schizophr Res 90:179-185
14 Kronfol Z, Remick DG (2000) Cytokines and the brain: implications for clinical psychiatry. Am J Psychiatry. 157:683-694
15 Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY (1995) Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res. 29:141-152
16 Maes M, De, Meester I, Scharpe S, Desnyder R, Ranjan R, Meltzer HY (1996) Alterations in plasma dipeptidyl peptidase IV enzyme activity in depression and schizophrenia: effects of antidepressants and antipsychotic drugs. Acta Psychiatr Scand. 93(1):1-8
17 Tsai SY, Yang YY, Kuo CJ, Chen CC, Leu SJ (2001) Effects of symptomatic severity on elevation of plasma soluble interleukin-2 receptor in bipolar mania. J Affect Disord. 64(2-3):185-193
18 Smith RS (1992) A comprehensive marcophage-T-lymphocyte theory of schizophrenia. Med Hypoth 39: 248-257
19 Rapaport MH, Guylai L, Whybrow P (1999) Immune parameters in rapid cycling bipolar patients before and after lithium treatment. J Psychiatr Res. 33(4):335-340
20 Su KP, Leu SJC, Yang YY, Shen WW, Chou YM, Tsai SY (2002) Reduced production of interferon-gamma but not interleukin-10 in bipolar mania and subsequent remission. J Affect Disord 71: 205-209
21 O''Brien SM, Scully P, Scott LV, Dinan TG (2006) Cytokine profiles in bipolar affective disorder: focus on acutely ill patients. J Affect Disord. 90(2-3):263-267
22 Zimmer S, Pollard V, Marshall GD, Garofalo RP, Traber D, Prough D, Herndon DN The 1996 Moyer Award. Effects of endotoxin on the Th1/Th2 response in humans. J Burn Care Rehabil. 17(6 Pt 1):491-496.
23 Guay HM, Andreyeva TA, Garcea RL, Welsh RM, Szomolanyi-Tsuda E (2007) MyD88 Is Required for the Formation of Long-Term Humoral Immunity to Virus Infection. J Immunol. 178(8):5124-5131
24 Lehner M, Morhart P, Stilper A, Petermann D, Weller P, Stachel D, Holter W (2007) Efficient Chemokine-dependent Migration and Primary and Secondary IL-12 Secretion by Human Dendritic Cells Stimulated Through Toll-like Receptors. J Immunother. 30(3):312-322
25 Camateros P, Tamaoka M, Hassan M, Marino R, Moisan J, Marion D, Guiot MC, Martin JG, Radzioch D. (2007) Chronic Asthma Induced Airway Remodeling is Prevented by the Toll-like Receptor 7/8 Ligand S28463. Am J Respir Crit Care Med. 175(12):1241-1249
26 American Psychiatric Association, (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th ed. American Psychiatric Association, Washington,DC. (DSM-IV).
27 AroltV, Rothermundt M, Peters M, Leonard B (2002) Immunological research in clinical psychiatry: report on the consensus debate during the 7th Expert Meeting on Psychiatry and Immunology. Mol. Psychiatry 7:822–826
28 Boey ML, Colaco CB,Gharavi AE, Elkon KB, Loizou S,Hughes GRV, (1983) Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant. Br. Med. J. 287:1021–1023
29 Canoso RT, deOliveira RM, Nixon RA, (1990) Neuroleptic-associated autoantibodies: a prevalence study. Biol. Psychiatry 27:863–870.
30 Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD, (1999) Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus 8:127–133
31 Cimaz R, Meroni PL, Shoenfeld Y, (2006) Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus 15:191–197.
32 Matsumoto M, Funami K, Oshiumi H, Seya T., 2004. Toll-like receptor 3: a link between toll-like receptor, interferon and viruses. Microbiol Immunol. 48, 147-154.
33 Vercammen E, Staal J, Beyaert R (2008) Sensing of viral infection and activation of innate immunity by toll-like receptor 3. Clin Microbiol Rev. 21:13-25.
34 Smith KD, Ozinsky A (2002) Toll-like receptor-5 and the innate immune response to bacterial flagellin. Curr Top Microbiol Immunol. 270:93-108.
35 Rumbo M, Nempont C, Kraehenbuhl JP, Sirard JC, (2006) Mucosal interplay among commensal and pathogenic bacteria: lessons from flagellin and Toll-like receptor 5. FEBS Lett. 580:2976-2984.

QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top